NCT06206278 2024-08-14
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
LianBio LLC
Phase 2 Terminated
Clinical Trials
11 trialsNCT03773302 2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04197986 2024-03-13
PROOF302
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT05222165 2023-02-23
NEWEL
Helsinn Healthcare SA
Phase 1/2 Withdrawn
NCT05019794 2022-06-27
FGFR
LianBio LLC
Phase 2 Unknown
NCT01928459 2020-12-09
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Novartis
Phase 1 Completed
NCT01697605 2020-12-08
A Phase I Study of Oral BGJ398 in Asian Patients
Novartis
Phase 1 Completed
NCT01975701 2019-12-04
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Novartis
Phase 2 Completed
NCT01004224 2019-10-04
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Novartis
Phase 1 Completed
NCT02160041 2019-06-18
CBGJ398XUS04
Novartis
Phase 2 Terminated